Ramesh V Chintala966 Hickory Ridge Dr, Chalfont, PA 18914

Get Report

Ramesh Chintala Phones & Addresses

966 Hickory Ridge Dr, Chalfont, PA 18914 (215) 822-6521

1118 Northumberland Way, Monmouth Junction, NJ 08852 (732) 438-1607

1124 Northumberland Way, Monmouth Junction, NJ 08852 (732) 438-1607

271 Pleasantview Dr, Piscataway, NJ 08854 (732) 926-0195

299 Pleasantview Dr, Piscataway, NJ 08854 (732) 926-0195

966 Hickory Ridge Dr, Chalfont, PA 18914

Work

Company: Merck & co., inc Aug 2012 Position: Assoc. principal scientist (assoc. director), vaccine drug product development

Education

School / High School: Rutgers University-New Brunswick- New Brunswick, NJ 2014 Specialities: mini MBA

Mentions for Ramesh V Chintala

Ramesh Chintala resumes & CV records

Resumes

Ramesh Chintala

Location:

West Point, PA

Industry:

Pharmaceuticals

Work:

Merck Aug 1, 2012 - Feb 2017
Associate Principal Scientist Enzon Pharmaceuticals Jul 2002 - Feb 2007
Scientist Rutgers University Jan 2001 - Jun 2002
Postdoctoral Associate Kyoto Pharmaceutical University Apr 1998 - Dec 2000
Postdoctoral Researcher

Education:

Rutgers University 1984 - 2014
Master of Business Administration, Masters, Biology University of Madras 1991 - 1997
Doctorates, Doctor of Philosophy, Philosophy, Chemistry University of Madras 1985 - 1990
Master of Science, Masters, Bachelors, Bachelor of Science, Chemistry

Skills:

Drug Discovery, Drug Development, Protein Chemistry, Biotechnology, Vaccines, Technology Transfer, Glp, Assay Development, Pharmaceutical Industry, Hplc, Chromatography, Biochemistry, In Vitro, Medicinal Chemistry, Purification, Chemistry, Molecular Biology, Biopharmaceuticals, Oncology, Drug Delivery, Formulation, Protein Expression, Cell, R&D, Characterization, Monoclonal Antibodies

Ramesh Chintala

Project Manager

Position:

Project Manager at IBM Global Services

Location:

Hyderabad, Andhra Pradesh, India

Industry:

Insurance

Work:

IBM Global Services - Hyderabad Area, India since Jul 2012
Project Manager

Education:

Pune Institute of Computer Technology

Ramesh Chintala

Ramesh Chintala - Chalfont, PA

Work:

Merck & Co., Inc Aug 2012 to 2000
Assoc. Principal Scientist (Assoc. Director), Vaccine Drug Product Development Merck & Co., Inc - West Point, PA Feb 2007 to Jul 2012
Research Fellow, Biologics & Vaccines Formulation Sciences Enzon Pharmaceuticals, Inc - Piscataway, NJ Jul 2002 to Feb 2007
Scientist II, Protein Chemistry Rutgers University - Piscataway, NJ Jan 2001 to Jun 2002
Postdoctoral Associate, Adviser Kyoto Pharmaceutical University Apr 1998 to Dec 2000
Postdoctoral Researcher, Adviser Central Leather Research Institute Oct 1997 to Mar 1998
Research Associate, Adviser Central Leather Research Institute Jan 1991 to Jun 1991
Research Assistant, Adviser

Education:

Rutgers University-New Brunswick - New Brunswick, NJ 2014
mini MBA University of Madras - Chennai, Tamil Nadu 1997
Ph. D. in Chemistry University of Madras - Chennai, Tamil Nadu 1988 to 1990
Master of Science in General Chemistry University of Madras - Chennai, Tamil Nadu 1985 to 1988
Bachelor of Science in Chemistry

Publications & IP owners

Us Patents

Dengue Virus Vaccine Compositions And Methods Of Use Thereof

US Patent:

2017036, Dec 21, 2017

Filed:

Dec 18, 2015

Appl. No.:

15/536319

Inventors:

Danilo R. CASIMIRO - West Point PA, US
Andrew BETT - West Point PA, US
Beth-Ann Griswold COLLER - West Point PA, US
Govindarajan DHANASEKARAN - West Point PA, US
Ramesh V. CHINTALA - West Point PA, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 39/12
C12N 7/00
A61K 39/00

Abstract:

The present invention relates to dengue virus vaccine compositions comprising a first and a second dengue vaccine, wherein the first dengue vaccine comprises at least one live, 5 attenuated dengue virus or live, attenuated chimeric dengue virus and the second dengue vaccine is a recombinant dengue subunit vaccine, a DNA vaccine, a conjugate vaccine, or an inactivated dengue vaccine; wherein the genome of the live attenuated dengue virus or the live attenuated chimeric dengue virus comprises a 30 nucleotide deletion of the TL2 stem-loop structure of the 3′ untranslated region. The dengue virus vaccine compositions of the invention may further 10 comprise one or more adjuvants. In preferred embodiments of the invention, the first and the second dengue vaccine are tetravalent. The invention also relates to methods of using the dengue virus vaccine compositions of the invention to treat or prevent dengue infection, or to prevent, ameliorate, or delay the onset or progression of the clinical manifestations thereof.

Dengue Virus Vaccine Compositions And Methods Of Use Thereof

US Patent:

2016015, Jun 2, 2016

Filed:

Jun 17, 2014

Appl. No.:

14/898515

Inventors:

Andrew Bett - Lansdale PA, US
Beth-Ann Griswold Coller - Kaneohe HI, US
Govindarajan Dhanasekaran - Harleysville PA, US
Ramesh V. Chintala - Chalfont PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 39/12

Abstract:

The present invention relates to dengue virus vaccine compositions comprising a first and a second dengue vaccine, wherein the first dengue vaccine is a live, attenuated dengue vaccine and the second dengue vaccine is a recombinant dengue subunit vaccine or an inactivated dengue vaccine; wherein the live attenuated dengue vaccine comprises at least one live, attenuated dengue virus or at least one live attenuated chimeric flavivirus. The dengue virus vaccine compositions of the invention may further comprise one or more adjuvants. In preferred embodiments of the invention, the first and the second dengue vaccine are tetravalent. The invention also relates to methods of using the dengue virus vaccine compositions of the invention to treat or prevent dengue infection, or to prevent, ameliorate, or delay the onset or progression of the clinical manifestations thereof.

Hpv Vaccine Formulations Comprising Aluminum Adjuvant And Methods Of Producing Same

US Patent:

2014012, May 8, 2014

Filed:

Jun 22, 2012

Appl. No.:

14/126992

Inventors:

Ramesh V. Chintala - Chalfont PA, US
Akhilesh Bhambhani - Doylestown PA, US

International Classification:

A61K 39/12

US Classification:

4242041

Abstract:

The invention provides human papillomavirus (HPV) antigen formulations which show increased antigen stability. More specifically, the invention provides stable HPV formulations comprising HPV virus-like particles (VLPs) bound to an aluminum salt adjuvant and further comprise a combination of sucrose and mannitol. The vaccine formulations of the invention are stable following freeze-thaw and freeze-drying. Also provided are lyophilized and frozen HPV vaccine formulations comprising HPV VLPs of at least one HPV type adsorbed onto an aluminum salt adjuvant, sucrose, and mannitol. Methods of making the stable vaccine formulations of the invention are also provided.

Possible Relatives

Ramesh J Newell Ramesh B Nair Ramesh Persaud Ramesh Singh Ramesh R Patel Ramesh P Prasad Ramesh K Rai Ramesh Gunda Ramesh M Rao Ramesh Abraham

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.